DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05444569

CompletedPhase 1

A Study of LY3537021 in Healthy Participants

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of LY3537021 When Combined With GLP-1 Receptor Agonist in Healthy Participants

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

47

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 23-40•Healthy volunteers

Primary endpoint

•Treatment-emergent AEs (any) (Treatment-emergent AEs (any), Serious AEs (any))

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05444569
Org study ID18449
Secondary IDJ2R-MC-YAACEli Lilly and Company

Timeline

Milestones

Study first posted2022-07-06actual
Study start2022-08-08actual
Primary completion2023-02-24actual
Study completion2023-02-24actual
Last update posted2023-03-01actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age21 Years
Maximum age60 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Participants who are overtly healthy as determined through medical evaluation
•Participants with body weight at least 55 kilograms (kg) and body mass index (BMI) of 23.0 to 40.0 kilograms per meter squared (kg/m²)
•Males, or females who are not of childbearing potential.
•Capable of giving signed informed consent form
•Have blood pressure of less than 150/90 millimeters of mercury (mm Hg) and pulse rate of less than 100 beats per minute (bpm) (supine)

Exclusion criteria

•Have a significant history of current disorders capable of significantly altering the absorption, metabolism or elimination of drugs
•History of malignancy within 5 years prior to screening
•Have evidence of significant active psychiatric disorder(s)
•Have undergone any form of bariatric surgery
•Have an abnormality in the 12-lead electrocardiogram (ECG)
•Are females who are lactating

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

1 endpoint
Primary/protocol endpoint

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Baseline up to Week 22

Treatment-emergent AEs (any)

event count, event

componentsTreatment-emergent AEs (any), Serious AEs (any)

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.